164 related articles for article (PubMed ID: 28377069)
1. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.
Yako YY; Brand M; Smith M; Kruger D
Pancreatology; 2017; 17(3):438-444. PubMed ID: 28377069
[TBL] [Abstract][Full Text] [Related]
2. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
4. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
Yako YY; Kruger D; Smith M; Brand M
PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.
Rahbari NN; Schmidt T; Falk CS; Hinz U; Herber M; Bork U; Büchler MW; Weitz J; Koch M
BMC Cancer; 2011 Jul; 11():286. PubMed ID: 21729304
[TBL] [Abstract][Full Text] [Related]
6. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma.
Chung HW; Jang S; Lim JB
Cancer; 2013 Jan; 119(1):233-44. PubMed ID: 22736451
[TBL] [Abstract][Full Text] [Related]
9. Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients.
Petrusel L; Ilies M; Leucuta D; Rusu I; Seicean A; Iuga C; Seicean R
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):107-112. PubMed ID: 34933726
[TBL] [Abstract][Full Text] [Related]
10. Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma.
Sabbaghian MS; Rothberger G; Alongi AP; Gagner JP; Goldberg JD; Rolnitzky L; Chiriboga L; Hajdu CH; Zagzag D; Basch R; Shamamian P
Anticancer Res; 2010 Jul; 30(7):2911-7. PubMed ID: 20683032
[TBL] [Abstract][Full Text] [Related]
11. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
[TBL] [Abstract][Full Text] [Related]
12. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.
Kruger D; Lahoud N; Yako YY; Devar J; Smith M
PLoS One; 2022; 17(1):e0262439. PubMed ID: 35020761
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
15. Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection.
Yang C; Bork U; Schölch S; Kulu Y; Kaderali L; Bolstorff UL; Kahlert C; Weitz J; Rahbari NN; Reissfelder C
Oncotarget; 2017 Sep; 8(42):72315-72323. PubMed ID: 29069789
[TBL] [Abstract][Full Text] [Related]
16. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
[TBL] [Abstract][Full Text] [Related]
20. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
